

Drugs and Therapeutics Committee Meeting Minutes – excerpt regarding liothyronine

Date and time: Thursday 17th May 2018

Agenda items

7.	TAG recommendations	Lead
	<p>The D&TC members discussed the TAG recommendations.</p> <p>Liothyronine – FM had replicated the current commissioning position for comparison against the PAC document. Correspondence had been received from the thyroid action group asking to be part of a sub group to consider how the treatment will be commissioned. Comments on the PAC document had been provided by the action group but had not been received until the morning of the TAG meeting. The group had asked that no decisions be made until their views had been taken into account. Unfortunately the lateness of receipt of the information had meant that there was insufficient time for the TAG members to consider the information. The question was raised as to whether the comments from the action group should be taken back to the TAG for further discussion at the next meeting.</p> <p>D&TC recommended that the PAC document be accepted. If the JSCC wish this to go back to TAG for further consideration, to include the comments raised by the action group, then the D&TCG asked that they be notified of this decision. The recommendation was that the treatment be commissioned in line with the PAC recommendations only, with initiation to remain within secondary care. NHS England had acknowledged that there may be a small cohort of patients in whom the treatment may be appropriate but these patients should be managed by an NHS endocrinologist. A pathway to be developed with the NHS endocrinologists.</p>	